NV4.BE - Cellectar Biosciences Inc

Berlin - Berlin Delayed price. Currency in EUR
1.6600
+0.1100 (+7.10%)
At close: 09:40PM CEST
Stock chart is not supported by your current browser
Previous close1.5500
Open1.5700
Bid1.5800 x N/A
Ask1.7300 x N/A
Day's range1.5700 - 1.6900
52-week range1.2100 - 6.4500
VolumeN/A
Avg. volume0
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date03 Aug 2023 - 07 Aug 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    UPDATE -- Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update

    FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update. First Quarter and Recent Corporate Highlights Presented at both the Roth Capital Partners 35th Annual Conference on March 13, 2023, and the Oppenheimer 33rd An

  • GlobeNewswire

    Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update

    FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update. First Quarter and Recent Corporate Highlights Presented at both the Roth Capital Partners 35th Annual Conference on March 13, 2023, and the Oppenheimer 33rd An

  • GlobeNewswire

    Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update

    FLORHAM PARK, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the year ended December 31, 2022 and provided a corporate update. Fourth Quarter and Recent Corporate Highlights Presented preclinical data on the CLR 12120 series of targeted alpha therapies (TATs) at the 13th Annual World ADC C

  • GlobeNewswire

    Cellectar to Participate at Upcoming Banking Conferences

    FLORHAM PARK, N.J., March 08, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced the company will participate in and be available for 1x1 meetings at the following upcoming conferences: Roth Capital Partners 35th Annual ConferenceDate: March 13, 2023Time: 8:30 – 8:55 AM ETFormat: Fireside Chat and available for 1x1 in

  • GlobeNewswire

    Cellectar Biosciences Reports Complete Response in a Relapsed/Refractory CNS Lymphoma Patient

    Response Achieved in Primary Central Nervous System Lymphoma for which there is no Approved TreatmentFLORHAM PARK, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that a patient with primary central nervous system lymphoma (PCNSL) enrolled in its Phase 2 CLOVER-1 Trial demonstrated a complete response

  • GlobeNewswire

    Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical

    FLORHAM PARK, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has hired Andrei Shustov, M.D., as its new Senior Vice President, Medical reporting to Mr. James Caruso, president and CEO. In this role, Dr. Shustov will lead and provide oversight on all aspects of the Company’s clinical developme

  • GlobeNewswire

    Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer

    FLORHAM PARK, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the appointment of Shane Lea as its chief commercial officer, effective November 21, 2022. Mr. Lea brings to Cellectar Biosciences comprehensive commercial leadership experience in hematology and oncology. In his most recent role as senior

  • GlobeNewswire

    Cellectar Biosciences Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference

    Preclinical data demonstrate ability to deliver targeted alpha-emitting isotopes to malignant cells and therapeutic efficacyFLORHAM PARK, N.J., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the presentation of preclinical data at the 13th Annual World ADC Conference supporting development of CLR 12120 ser

  • GlobeNewswire

    Cellectar Announces Resolution of Breach of Contract and Intellectual Property Dispute

    Secures license to the patents at issue in the lawsuitFLORHAM PARK, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced that Cellectar Biosciences, Inc., Wisconsin Alumni Research Foundation, and Drs. Jamey Weichert and Anatoly Pinchuk have resolved a lawsuit filed by Cellectar in October 2021 in the United States Di

  • GlobeNewswire

    Cellectar Reports Financial Results for Third Quarter 2022 and Provides a Corporate Update

    FLORHAM PARK, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the third quarter ended September 30, 2022 and provided a corporate update. Third Quarter and Recent Corporate Highlights In October, the company closed concurrent registered direct and private placement offerings totaling $10.7 m

  • GlobeNewswire

    Cellectar Biosciences Announces Closing of Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules

    FLORHAM PARK, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has closed on its previously announced definitive agreements with several institutional investors (the “Investors”) to purchase 3,275,153 shares of the company’s common stock at $2.085 per share in a registered direct offering and w

  • GlobeNewswire

    Cellectar Biosciences Announces Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules

    FLORHAM PARK, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has entered into definitive agreements with several institutional investors (the “Investors”) for the purchase of 3,275,153 shares of the company’s common stock at $2.085 per share in a registered direct offering and warrants to pur

  • GlobeNewswire

    Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors

    FLORHAM PARK, N.J., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced it has been awarded $1.98 million in additional grant funding to expand its ongoing Phase 1 study of iopofosine I 131 (iopofosine) in children and adolescents with inoperable relapsed or refractory high grade gliomas (HGGs). The grant was awarded by t

  • GlobeNewswire

    Cellectar Announces Publication of Data from Its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma in Nature’s Blood Cancer Journal

    Initial data show ORR of 50% in Quad-Class Refractory Multiple Myeloma Patients Who Have Failed anti-BCMA Immunotherapy with Median of Nine Lines of Prior TherapyFLORHAM PARK, N.J., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced the publication of a paper highlighting data from an expansion cohort of the ongoing Phas

  • Simply Wall St.

    Will Cellectar Biosciences (NASDAQ:CLRB) Spend Its Cash Wisely?

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

  • GlobeNewswire

    Cellectar Reports Financial Results for Second Quarter 2022

    FLORHAM PARK, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the second quarter ended June 30, 2022. “During the second quarter, iopofosine passed an important milestone as an independent data monitoring committee completed a futility/efficacy assessment and unanimously recommended continua